AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
198.26
-0.38 (-0.19%)
Aug 12, 2025, 3:35 PM - Market open
Paramount Global Revenue
AbbVie had revenue of $15.42B in the quarter ending June 30, 2025, with 6.65% growth. This brings the company's revenue in the last twelve months to $58.33B, up 6.05% year-over-year. In the year 2024, AbbVie had annual revenue of $56.33B with 3.71% growth.
Revenue (ttm)
$58.33B
Revenue Growth
+6.05%
P/S Ratio
6.02
Revenue / Employee
$1,060,509
Employees
55,000
Market Cap
350.24B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
Thermo Fisher Scientific | 43.21B |
ABBV News
- 2 hours ago - AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S. - PRNewsWire
- 4 days ago - Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% - Benzinga
- 6 days ago - Get Ready, JUVÉDERM® Day is Calling! - PRNewsWire
- 7 days ago - Allergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency - PRNewsWire
- 11 days ago - AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion - Benzinga
- 11 days ago - 5 Dividend Stocks With Solid Returns And More Growth Ahead - Benzinga
- 11 days ago - Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges - WSJ
- 12 days ago - Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says - Forbes